Asset Details
Do you wish to reserve the book?
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
Do you wish to request the book?
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
2013
Overview
Two cases of progressive multifocal leukoencephalopathy (PML) are reported in patients with psoriasis who were treated with fumarates, one with Fumaderm and the other with a compound containing dimethyl fumarate. The manufacturer of Fumaderm comments on the reports.
To the Editor:
Preparations containing various mixtures of fumaric acid esters are prescribed for psoriasis in several countries, in many cases for off-label use, and are regarded as safe.
1
One such preparation is enteric-coated, slow-release Psorinovo (compounding pharmacy, Mierlo-Hout), in which the active agent is dimethyl fumarate and in which copper gluconate was used as an additive until 2010 (for a profile of the drug, see the Supplementary Appendix, available with the full text of this letter at NEJM.org).
On November 5, 2012, a 42-year-old woman who reported having progressive right-sided hemiparesis since May consulted us for a second opinion. She . . .
Publisher
Massachusetts Medical Society
Subject
/ Dermatologic Agents - adverse effects
/ Dermatologic Agents - therapeutic use
/ Female
/ Humans
/ Leukoencephalopathy, Progressive Multifocal - chemically induced
/ Leukoencephalopathy, Progressive Multifocal - pathology
/ NMR
/ Paresis - chemically induced
/ Pharmacy
